GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther

Dorothy Hodgkin Building, Whitson St, Bristol BS1 3NY UK. Electronic address: .
Pharmacology [?] Therapeutics (Impact Factor: 9.72). 01/2013; 138(2). DOI: 10.1016/j.pharmthera.2013.01.004
Source: PubMed


Glial cell-derived neurotrophic factor (GDNF), and the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are important for the survival, maintenance and regeneration of specific neuronal populations in the adult brain. Depletion of these neurotrophic factors has been linked with disease pathology and symptoms, and replacement strategies are considered as potential therapeutics for neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's disease. GDNF administration has recently been shown to be an effective treatment for Parkinson's disease, with clinical trials currently in progress. Trials with NGF for Alzheimer's disease are ongoing, with some degree of success. Preclinical results using BDNF also show much promise, although there are accompanying difficulties. Ultimately, the administration of a therapy involving proteins in the brain has inherent problems. Because of the blood-brain-barrier, the protein must be infused directly, produced by viral constructs, secreted from implanted protein-secreting cells or actively transported across into the brain. An alternative to this is the use of a small molecule agonist, a modulator or enhancer targeting the associated receptors. We evaluate these neurotrophic factors as potential short or long-term treatments, weighing up preclinical and clinical results with the possible effects on the underlying neurodegenerative process.

Download full-text


Available from: Deborah Karen Shoemark, Oct 03, 2015
361 Reads
  • Source
    • "Several studies have confirmed that brief bouts of (intense) aerobic exercise result in a transient increase in circulating IGF-1 and BDNF. Gene expression and secretion of BDNF in the brain is mainly regulated in an activity-dependent manner, which might explain why BDNF, among all neurotrophins, is most consistently upregulated with exercise (Allen et al. 2013). The mechanisms/ stimuli responsible for this exercise-induced increase have not yet been clearly established, but some hypotheses are proposed in literature. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Exercise is known to have beneficial effects on cognitive function. This effect is greatly favored by an exercise-induced increase in neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1), especially with high-intensity exercises (HIE). As a complication of type 1 diabetes (T1D), a cognitive decline may occur, mostly ascribed to hypoglycaemia and chronic hyperglycaemia. Therefore, the purpose of this study was to examine the effects of acute HIE on cognitive function and neurotrophins in T1D and matched controls. Ten trained T1D (8 males, 2 females) participants and their matched (by age, sex, fitness level) controls were evaluated on 2 occasions after familiarization: a maximal test to exhaustion and an HIE bout (10 intervals of 60 s at 90% of their maximal wattage followed by 60 s at 50 W). Cognitive tests and analyses of serum BDNF, IGF-1, and free insulin were performed before and after HIE and following 30 min of recovery. At baseline, cognitive performance was better in the controls compared with the T1D participants (p < 0.05). After exercise, no significant differences in cognitive performance were detected. BDNF levels were significantly higher and IGF-1 levels were significantly lower in T1D compared with the control group (p < 0.05) at all time points. Exercise increased BDNF and IGF-1 levels in a comparable percentage in both groups (p < 0.05). In conclusion, although resting levels of serum BDNF and IGF-1 were altered by T1D, comparable increasing effects on BDNF and IGF-1 in T1D and healthy participants were found. Therefore, regularly repeating acute HIE could be a promising strategy for brain health in T1D.
    Applied Physiology Nutrition and Metabolism 01/2015; 40(1). DOI:10.1139/apnm-2014-0098 · 2.34 Impact Factor
  • Source
    • "To verify that PB-IPCs-derived astrocyte-like cells possess neurotrophic functions, we tested the mRNA expression of several neurotrophic factors, including BDNF, NGF and GDNF, which play important protective roles in some neurodegenerative diseases, such as Alzheimer's and Parkinson's (Allen et al., 2013). BDNF mRNA is more strongly expressed in PB-IPCs than GDNF or NGF mRNA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have previously reported a novel CD45-positive cell population called peripheral blood insulin-producing cells (PB-IPCs) and its unique potential for releasing insulin in vitro. Despite the CD45-positive phenotype and self-renewal ability, PB-IPCs are distinguished from hemopoietic and endothelial progenitor cells (EPCs) by some characteristics, such as a CD34-negative phenotype and different culture conditions. We have further identified the gene profiles of the embryonic and neural stem cells, and these profiles include Sox2, Nanog, c-Myc, Klf4, Notch1 and Mash1. After treatment with all-trans retinoic acid (ATRA) in vitro, most PB-IPCs exhibited morphological changes that included the development of elongated and branched cell processes. In the process of induction, the mRNA expression of Hes1 was robustly upregulated, and a majority of cells acquired some astrocyte-associated specific phenotypes including anti-glial fibrillary acidic protein (GFAP), CD44, Glutamate-aspartate transporter (GLAST) and S100β. In spite of the deficiency of glutamate uptaking, the differentiated cells significantly relaxed the regulation of the expression of brain-derived neurotrophic factor (BDNF) mRNA. This finding demonstrates that PB-IPCs could be induced into a population of astrocyte-like cells and enhanced the neurotrophic potential when the state of proliferation was limited by ATRA, which implicates that this unique CD45+ cell pool may have a protective role in some degenerative diseases of the central nervous system (CNS).
    Cell Biology International 01/2015; 39(1). DOI:10.1002/cbin.10355 · 1.93 Impact Factor
  • Source
    • "As shown previously, melatonin may partially contribute to restoration of brain energy metabolism by increasing growth hormone and IGF-1 levels in animals with ADlike pathology (Jenwitheesuk et al. 2014). It is generally accepted that BDNF levels are lowered in the hippocampus and cortex of patients with AD (Allen et al. 2013). The results that we obtained in the assays of BDNF levels in the hippocampus of four-month-old OXYS rats are surprising. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Melatonin synthesis is disordered in patients with Alzheimer’s disease (AD). To determine the role of melatonin in the pathogenesis of AD, suitable animal models are needed. The OXYS rats are an experimental model of accelerated senescence that has also been proposed as a spontaneous rat model of AD-like pathology. In the present study, we demonstrate that disturbances in melatonin secretion occur in OXYS rats at 4 months of age. These disturbances occur simultaneously with manifestation of behavioral abnormalities against the background of neurodegeneration and alterations in hormonal status but before the signs of amyloid-β accumulation. We examined whether oral administration of melatonin could normalize the melatonin secretion and have beneficial effects on OXYS rats before progression to AD-like pathology. The results showed that melatonin treatment restored melatonin secretion in the pineal gland of OXYS rats as well as the serum levels of growth hormone and IGF-1, the level of BDNF in the hippocampus and the healthy state of hippocampal neurons. Additionally, melatonin treatment of OXYS rats prevented an increase in anxiety and the decline of locomotor activity, of exploratory activity, and of reference memory. Thus, melatonin may be involved in AD progression, whereas oral administration of melatonin could be a prophylactic strategy to prevent or slow down the progression of some features of AD pathology.
    Biogerontology 12/2014; 16(3). DOI:10.1007/s10522-014-9547-7 · 3.29 Impact Factor
Show more